

## **Lupin finalizes patent sale agreement with Servier**

<b>BSE : 500257</b>
---------------------

<b>NSE: Lupin</b>
-------------------

<b>REUTERS: LUPN.BO</b>
-------------------------

<b>BLOOMBERG: LPC IN</b>
--------------------------

**Mumbai, 5<sup>th</sup> April 2007:** Further to its announcement on February 20<sup>th</sup> 2007, and pursuant to signing a definitive patent sale agreement, Lupin Limited announced today that the company has received Euro 20mn from Laboratoires Servier of France for the sale of certain patent applications and other related Intellectual Property for Perindopril for multiple countries.

“The income from this sale significantly boosts our performance for the previous quarter. It obviously goes a long way to demonstrate our Research and IP capabilities,” said Dr. Kamal Sharma, Managing Director, Lupin Ltd.

### **About Lupin**

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the nine-month period ended December 2006, the Company's Revenues and Profit after Tax were Rs.14,985 million (US\$ 335 million) and Rs.1,650 million (US\$ 37 million) respectively.

### **For further information contact:**

Raju Kane

The Source

Tel. +91 22 24901327/28

Telefax: +91 22 24901325

Mobile: +91 98200 45656

E-mail: [rajukane@sourcepr.com](mailto:rajukane@sourcepr.com)